Publications by authors named "A J N Raymakers"
Costly targeted cancer treatments challenge publicly-funded healthcare systems seeking to align expected benefit with value for money. In 2021, The Canadian Agency for Drugs and Technologies in Health (CADTH) published a provisional funding algorithm for risk-based treatment of chronic lymphocytic leukemia (CLL). We estimate the cost-effectiveness of this algorithm against current standard of care.
View Article and Find Full Text PDFDrug repurposing faces various challenges that can impede its success. We developed a framework outlining key challenges in drug repurposing to explore when and how health technology assessment (HTA) methods can address them. We identified 20 drug-repurposing challenges across the categories of data access, research and development, collaboration, business case, regulatory and legal challenges.
View Article and Find Full Text PDFRecurrence rate and patient-reported outcomes after wedge excision of carpal boss.
J Plast Reconstr Aesthet Surg
May 2024
The treatment of carpal boss is primarily conservative. Surgical treatment by performing a wedge excision of the bony protrusion, is possible. However, a common belief exists that carpal boss should not be operated because of the high recurrence rate.
View Article and Find Full Text PDFArticle Synopsis
- - The US currently does not have a clear method to connect drug prices with their clinical benefits, and traditional cost-effectiveness analysis faces political hurdles; the efficiency frontier (EF) method presents a new option for policymakers.
- - This study evaluated the EF method for pricing and clinical benefits of biologic drugs treating plaque psoriasis in the US versus Australia, Canada, France, and Germany, utilizing data from early 2023.
- - Results showed significant differences in treatment costs and effectiveness; US prices for biologics were generally higher than those in the peer countries, with the most effective treatments having widely varying annual costs.